| 名稱 | AI-Edigene® EGFR p.L861Q Reference Standard P |
| 型號(hào) | CBP10401 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | AI-Edigene® EGFR p.L861Q Reference Standard Plus |
產(chǎn)品搜索
相關(guān)文章
- CYP2C19基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 治療疼痛的潛力靶點(diǎn)——NGF
- 細(xì)胞株開發(fā)的主要過程要知道
- BCMA靶點(diǎn)藥物細(xì)胞篩選模型
- 【連載-企業(yè)參考品】 急性淋巴細(xì)胞白血病的診斷參考品的選擇
- 實(shí)驗(yàn)?zāi)芊裰貜?fù)仍在持續(xù)：誰來給韓春雨事件畫上句號(hào)？
- ATCC細(xì)胞單純的固定液一般難以達(dá)到這些要求
- ATCC細(xì)胞株開發(fā)的四階段簡介
- PD-1/L1 &4-1BB雙靶點(diǎn)細(xì)胞篩選模型
- 基于納米顆粒的組合免疫療法對致命性癌癥發(fā)起三重打擊
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測標(biāo)準(zhǔn)品 > Mutation > CBP10401AI-Edigene® EGFR p.L861Q Reference Standard P
- 詳細(xì)內(nèi)容
" _ue_custom_node_="true">
CBP10401 | |
| Format | Genomic DNA |
| Description | The L861Q mutation results in an amino acid substitution at position 861 in EGFR, from a leucine (L) to a glutamine (Q). This mutation occurs within exon 21, which encodes part of the kinase domain, and occurs with a frequency of approximately 2% in EGFR-mutated lung tumors (Mitsudomi and Yatabe 2010). This mutation is associated with increased sensitivity to the EGFR TKIs, erlotinib (Tarceva) and gefitinib (Iressa; Lynch et al. 2004). |
| Technical Data | |
| DNA Change | c.2582T>A |
| AA Change | p.L861Q |
| Mutation type | Substitution - Missense |
| Zygosity | Homozygous |
| Allelic Frequency | 100% |
| Transcript | ENST00000275493 |
| Cosmic ID | COSM6213 |
| Chr position(GRCh37) | chr7:55259524 |
| Buffer | Tris-EDTA |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purofication | Download for COA |
| DNA electrophoresis | Download for COA |
| Sanger sequencing |
|
| Storage | 4℃ |
| Expiry | 36 months from the date of manufacture |
會(huì)員_a.png)